Compare ITGR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | TLX |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | 2000 | 2024 |
| Metric | ITGR | TLX |
|---|---|---|
| Price | $126.70 | $10.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $121.80 | $20.74 |
| AVG Volume (30 Days) | ★ 678.5K | 399.0K |
| Earning Date | 10-30-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $1,853,637,000.00 | N/A |
| Revenue This Year | N/A | $16.05 |
| Revenue Next Year | $5.96 | $13.75 |
| P/E Ratio | ★ $108.32 | $150.33 |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $62.00 | $6.28 |
| 52 Week High | $126.80 | $13.11 |
| Indicator | ITGR | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 72.72 | 43.99 |
| Support Level | $126.16 | $10.01 |
| Resistance Level | $126.80 | $11.48 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.21 | -0.04 |
| Stochastic Oscillator | 79.41 | 23.14 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.